MA53496A - Combinaisons pour le traitement de la stéatohépatite non alcoolique (nash)/maladie du foie gras non alcoolique (nafld) et de maladies associées - Google Patents

Combinaisons pour le traitement de la stéatohépatite non alcoolique (nash)/maladie du foie gras non alcoolique (nafld) et de maladies associées

Info

Publication number
MA53496A
MA53496A MA053496A MA53496A MA53496A MA 53496 A MA53496 A MA 53496A MA 053496 A MA053496 A MA 053496A MA 53496 A MA53496 A MA 53496A MA 53496 A MA53496 A MA 53496A
Authority
MA
Morocco
Prior art keywords
alcoholic
nafld
nash
combinations
treatment
Prior art date
Application number
MA053496A
Other languages
English (en)
Inventor
William Paul Esler
Trenton Thomas Ross
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA53496A publication Critical patent/MA53496A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
MA053496A 2018-08-31 2019-08-28 Combinaisons pour le traitement de la stéatohépatite non alcoolique (nash)/maladie du foie gras non alcoolique (nafld) et de maladies associées MA53496A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862726172P 2018-08-31 2018-08-31
US201962883860P 2019-08-07 2019-08-07

Publications (1)

Publication Number Publication Date
MA53496A true MA53496A (fr) 2021-12-08

Family

ID=68165623

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053496A MA53496A (fr) 2018-08-31 2019-08-28 Combinaisons pour le traitement de la stéatohépatite non alcoolique (nash)/maladie du foie gras non alcoolique (nafld) et de maladies associées

Country Status (22)

Country Link
US (2) US11254660B2 (fr)
EP (1) EP3843740A1 (fr)
JP (1) JP7161605B2 (fr)
KR (1) KR102614808B1 (fr)
CN (1) CN112955147A (fr)
AU (1) AU2019329884B2 (fr)
BR (1) BR112021003039A2 (fr)
CA (1) CA3110601C (fr)
CL (1) CL2021000491A1 (fr)
CO (1) CO2021002230A2 (fr)
CR (1) CR20210110A (fr)
DO (1) DOP2021000036A (fr)
EC (1) ECSP21012501A (fr)
IL (1) IL281093B2 (fr)
MA (1) MA53496A (fr)
MX (1) MX2021002428A (fr)
PH (1) PH12021550339A1 (fr)
SG (1) SG11202101503RA (fr)
TW (1) TWI718644B (fr)
UY (1) UY38351A (fr)
WO (1) WO2020044266A1 (fr)
ZA (1) ZA202101090B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
MX2021006034A (es) 2018-11-22 2021-09-21 Qilu Regor Therapeutics Inc Agonistas de glp-ir y usos de los mismos.
JP2022516509A (ja) * 2018-12-31 2022-02-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）を治療するための組成物および方法
US10954221B2 (en) 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
MD4097099T2 (ro) 2020-02-07 2025-02-28 Gasherbrum Bio Inc Agonişti GKP-1 heterociclici
JP2021134211A (ja) * 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
JP2022058085A (ja) * 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
WO2021182876A1 (fr) * 2020-03-11 2021-09-16 동아에스티 주식회사 Composition pharmaceutique pour la prévention ou le traitement d'une stéatohépatite non alcoolique
WO2021211959A2 (fr) * 2020-04-18 2021-10-21 Inipharm, Inc. Procédés et compositions pour le traitement de la stéatohépatite induite par un médicament
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
CN113816948B (zh) * 2020-06-19 2023-08-11 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
CR20230066A (es) 2020-08-06 2023-05-29 Gasherbrum Bio Inc Agonistas del glp-1 heterocíclicos
MX2023002108A (es) * 2020-08-21 2023-07-11 Terns Pharmaceuticals Inc Compuestos como agonistas de glp-1r.
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
CN112635049A (zh) * 2020-12-23 2021-04-09 无锡市第二人民医院 一种研究HSD17B13 rs72613567基因变异和肾功能损伤之间关系的方法
WO2023049518A1 (fr) 2021-09-27 2023-03-30 Terns Pharmaceuticals, Inc. Acides benzimidazole carboxyliques utilisés en tant qu'agonistes de glp-1r
TW202334129A (zh) 2021-10-25 2023-09-01 美商拓臻製藥公司 作為ｇｌｐ—１ｒ促效劑的化合物
US12410163B2 (en) 2022-02-23 2025-09-09 Terns Pharmaceuticals, Inc. Compounds as GLP-IR agonists
WO2023169456A1 (fr) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Agonistes hétérocycliques de glp-1
JP2025513071A (ja) 2022-04-14 2025-04-22 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
KR20250157491A (ko) 2022-12-15 2025-11-04 가셔브룸 바이오, 인크. Glp-1 효능제 활성을 갖는 화합물의 염 및 고체 형태
AU2024251995A1 (en) 2023-04-07 2025-11-27 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease
AU2024314133A1 (en) * 2023-06-20 2026-01-15 Sagimet Biosciences Inc. Combination therapies of fasn inhibitors with thyroid hormone receptor agonists
WO2025080818A1 (fr) * 2023-10-10 2025-04-17 Sagimet Biosciences Inc. Combinaisons d'inhibiteurs de fasn et d'agonistes de glp-1 pour des maladies hépatiques
CN118787746B (zh) * 2024-07-01 2025-09-16 安徽省立医院(中国科学技术大学附属第一医院) 脂肪酸合成酶抑制剂在预防及治疗药物性肝损伤中的应用
CN120698959B (zh) * 2025-05-29 2026-01-23 河北医科大学 一种达格列净-依折麦布共无定形物及其制备方法和应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (fr) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Procede de production d'un compose pharmaceutique a liberation continue sous forme solide
DE3065190D1 (en) 1979-11-05 1983-11-10 Beecham Group Plc Enzyme derivatives, and their preparation
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
TR200100149T2 (tr) 1998-07-06 2001-10-22 Bristol-Myers Squibb Company Dual anjiyotensin endotelin alıcı antagonistleri olarak bifenil-sülfonamitler
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
GEP20053710B (en) 2001-02-28 2005-12-26 Merck & Co Inc Acylated Piperidine Derivatives as Melanocortin-4 Receptor Agonists
EP1478437B1 (fr) 2002-02-27 2005-08-31 Pfizer Products Inc. Inhibiteurs de l'acetyl-coa-carboxylase
WO2005116014A1 (fr) 2004-05-12 2005-12-08 Pfizer Products Inc. Derives de proline et leur utilisation en tant qu'inhibiteurs de la dipeptidyl-peptidase iv
EP1753766A1 (fr) 2004-05-25 2007-02-21 Pfizer Products Inc. Derives de tetraazabenzo(e)azulene et analogues de ceux-ci
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
WO2007122482A1 (fr) 2006-04-20 2007-11-01 Pfizer Products Inc. Composés phényle amido-hétérocycliques fusionnés pour la prévention et le traitement de maladies à médiation par glucokinase
US20090270435A1 (en) 2006-11-29 2009-10-29 Jeffrey Wayne Corbett Spiroketone Acetyl-CoA Carboxylase Inhibitors
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
CA2724774C (fr) 2008-05-28 2013-06-25 Pfizer Inc. Inhibiteurs de la pyrazolospirocetone acetl-coa carboxylase
CA2724603A1 (fr) 2008-05-28 2009-12-03 Pfizer Inc. Inhibiteurs de la pyrazolospirocetone acetyl-coa carboxylase
EP2318370A1 (fr) 2008-07-29 2011-05-11 Pfizer Inc. Hétéroaryles fluorés
PE20110288A1 (es) 2008-08-28 2011-05-26 Pfizer Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
WO2010086820A1 (fr) 2009-02-02 2010-08-05 Pfizer Inc. Dérivés de 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazépin-6(5h)-yl)phényle
WO2010103438A1 (fr) 2009-03-11 2010-09-16 Pfizer Inc. Indazole amides substitués
AP3179A (en) 2009-03-11 2015-03-31 Pfizer Benzofuranyl derivatives used as glucokinase inhibitors
EP2408780A2 (fr) 2009-03-20 2012-01-25 Pfizer Inc. 3-oxa-7-azabicycloý3,3.1¨nonanes
WO2010128425A1 (fr) 2009-05-08 2010-11-11 Pfizer Inc. Modulateurs de gpr119
WO2010128414A1 (fr) 2009-05-08 2010-11-11 Pfizer Inc. Modulateurs du gpr119
EP2438051A1 (fr) 2009-06-05 2012-04-11 Pfizer Inc. Derives de l-(piperidin-4-yl)-pyrazole utilises en tant que modulateurs du gpr 119
WO2011005611A1 (fr) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Agonistes du récepteur de la neuromédine u et leurs utilisations
CH702192A1 (de) 2009-11-04 2011-05-13 New Dent Ag Keramisches Implantat.
PL2621493T3 (pl) * 2010-09-30 2017-01-31 Pfizer Inc. N1-pirazolospiroketonowe inhibitory karboksylazy acetylo-CoA
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
CN107106873A (zh) 2015-01-09 2017-08-29 吉利德阿波罗公司 用于治疗非酒精性脂肪肝病的acc抑制剂组合治疗
CU24540B1 (es) 2015-12-29 2021-08-06 Pfizer 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
AR109179A1 (es) * 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
CN106271089B (zh) 2016-09-30 2019-01-25 英诺激光科技股份有限公司 一种激光薄膜刻蚀装置及方法
HRP20221437T1 (hr) 2016-12-16 2023-02-03 Pfizer Inc. Agonisti receptora glp-1 i njihova upotreba
IL274820B2 (en) 2017-11-21 2024-11-01 Pfizer Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid

Also Published As

Publication number Publication date
TWI718644B (zh) 2021-02-11
ECSP21012501A (es) 2021-03-31
CA3110601C (fr) 2023-09-05
JP7161605B2 (ja) 2022-10-26
AU2019329884B2 (en) 2022-01-27
CO2021002230A2 (es) 2021-03-08
DOP2021000036A (es) 2021-04-15
AU2019329884A1 (en) 2021-03-11
IL281093B2 (en) 2025-11-01
MX2021002428A (es) 2023-01-02
KR102614808B1 (ko) 2023-12-19
PH12021550339A1 (en) 2021-10-04
EP3843740A1 (fr) 2021-07-07
ZA202101090B (en) 2022-06-29
UY38351A (es) 2020-03-31
CL2021000491A1 (es) 2021-08-20
US12247022B2 (en) 2025-03-11
IL281093A (en) 2021-04-29
IL281093B1 (en) 2025-07-01
TW202026292A (zh) 2020-07-16
US20200071306A1 (en) 2020-03-05
US11254660B2 (en) 2022-02-22
WO2020044266A1 (fr) 2020-03-05
JP2021535126A (ja) 2021-12-16
CN112955147A (zh) 2021-06-11
US20220023299A1 (en) 2022-01-27
CR20210110A (es) 2021-05-13
KR20210053929A (ko) 2021-05-12
SG11202101503RA (en) 2021-03-30
BR112021003039A2 (pt) 2021-05-18
CA3110601A1 (fr) 2020-03-05

Similar Documents

Publication Publication Date Title
MA53496A (fr) Combinaisons pour le traitement de la stéatohépatite non alcoolique (nash)/maladie du foie gras non alcoolique (nafld) et de maladies associées
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP3710831A4 (fr) Marqueurs pour le diagnostic et le traitement de la stéatohépatite non alcoolique (nash) et de la fibrose hépatique avancée
EP3976189C0 (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EA201790124A1 (ru) Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
IL287796A (en) Compositions and methods for the treatment of atpase-mediated diseases
MA46219A (fr) Composés de co-agonistes du glucagon et du glp-1
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
EP3427051A4 (fr) Biomarqueurs protéiques et d'auto-anticorps pour le diagnostic et le traitement du cancer du poumon
MX2021003156A (es) Tratamiento para la enfermedad del higado graso no alcoholico.
EP3781158A4 (fr) Compositions pour le traitement de la maladie du foie gras non alcoolique et de la stéatohépatite non alcoolique
EP3326640A4 (fr) Application de la protéine de moule à action adhésive pour le traitement et la prévention de maladies associées à la mélanine
EP3685840A4 (fr) Composition pharmaceutique de composés pour traiter des maladies cutanées inflammatoires
EP3986426A4 (fr) Ciblage de l'intégrine alpha3bêta1 pour le traitement du cancer et d'autres maladies
MA53614A (fr) Protéine pour le traitement de maladies inflammatoires
IL290891A (en) Compositions and methods of treating vascular diseases
MX2019014365A (es) Tratamiento topico de la enfermedad intestinal inflamatoria usando anticuerpos y fragmentos de los mismos.
EP3510014A4 (fr) Compositions et procédés d'utilisation de capteurs de gamma-cétoaldéhyde pour le traitement, la prévention ou l'amélioration de la maladie du foie gras non alcoolique (nafld), de nash, de l'ald ou d'états associés au foie
EP4054568A4 (fr) Analogues de thiazolidinedione pour le traitement d'une nafld et de maladies métaboliques
EP3597198A4 (fr) Composition pour traitement des maladies articulaires, et kit contenant cette composition
EP3530278A4 (fr) Composition comprenant un peptide inhibiteur de protéine phosphatase 1 pour le traitement des maladies vasculaires
EP3880709A4 (fr) Schéma posologique d'un anticorps anti-lag3 et polythérapie avec un anticorps anti-pd-1 pour le traitement du cancer
EP3802568A4 (fr) Agents thérapeutiques peptidiques pour le traitement de la maladie d'alzheimer et d'états apparentés